Return to site

Bioburden Testing Market Emerging Trends 2019

The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Factors such as growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination are expected to drive the growth of this market during the forecast period. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years.

Based on product, the bioburden testing market is segmented into consumables and instruments. In 2018, the consumables segment is expected to account for the largest share of the global bioburden testing market. This segment is also projected to register the highest CAGR during the forecast period. The long shelf life and the recurrent purchase of media, kits, and reagents are driving the adoption of bioburden testing consumables.
On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest market share in 2018, and this trend is expected to continue during the forecast period. The large size of the North American biotechnology industry will aid the growth of the bioburden testing market in this region. However, the Asian market is expected to witness the highest growth during the forecast period. Strong investments and rapid growth in the pharmaceutical and biotechnology industries will drive the growth of the bioburden testing market in this region.
Pharmaceutical and biotechnology companies are the major end users of the bioburden testing market. In the pharmaceutical industry, bioburden testing is required at the quality control stage for raw materials, drugs, and other resources which are used in the manufacturing process. In the pharmaceutical manufacturing industry, bioburden testing is required to obtain regulatory approvals for products.
Players in the bioburden testing market are adopting organic and inorganic growth strategies to further strengthen their presence and expand their product portfolios in the market. Some notable developments in this regard have been mentioned below:

In 2018, WuXi AppTec opened a Medical Device Testing center in China.

In 2018, Charles River acquired MPI Research, a premier nonclinical contract research organization (CRO).

In 2016, SGS acquired Quality Compliance Laboratories to provide microbiological and analytical testing services to pharmaceutical, nutraceutical, and cosmeceutical industries.

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly